Format

Send to

Choose Destination
J Am Coll Cardiol. 2015 Jul 21;66(3):278-307. doi: 10.1016/j.jacc.2015.05.046.

Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium.

Author information

1
Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York. Electronic address: gs2184@columbia.edu.
2
Hôpital Bichat, Paris, France.
3
Mount Sinai Health System, New York, New York.
4
The Ohio State University, Columbus, Ohio.
5
SUNY Downstate Medical Center, Brooklyn, New York.
6
Leiden University Medical Center, Leiden, the Netherlands.
7
Hamburg University Cardiovascular Center, Hamburg, Germany.
8
Beth Israel Deaconess Medical Center, Boston, Massachusetts.
9
Duke University Medical Center, Durham, North Carolina.
10
Cleveland Clinic, Cleveland, Ohio.
11
Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York; Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.
12
Baylor University Medical Center, Dallas, Texas.
13
Cedars-Sinai Medical Center, Los Angeles, California.
14
Mayo Clinic, Rochester, Minnesota.
15
University Hospital of Liège, Liège, Belgium.
16
Athens University Hospital Attikon, Athens, Greece.
17
Erasmus University Medical Center, Rotterdam, the Netherlands.

Abstract

Mitral regurgitation (MR) is one of the most prevalent valve disorders and has numerous etiologies, including primary (organic) MR, due to underlying degenerative/structural mitral valve (MV) pathology, and secondary (functional) MR, which is principally caused by global or regional left ventricular remodeling and/or severe left atrial dilation. Diagnosis and optimal management of MR requires integration of valve disease and heart failure specialists, MV cardiac surgeons, interventional cardiologists with expertise in structural heart disease, and imaging experts. The introduction of transcatheter MV therapies has highlighted the need for a consensus approach to pragmatic clinical trial design and uniform endpoint definitions to evaluate outcomes in patients with MR. The Mitral Valve Academic Research Consortium is a collaboration between leading academic research organizations and physician-scientists specializing in MV disease from the United States and Europe. Three in-person meetings were held in Virginia and New York during which 44 heart failure, valve, and imaging experts, MV surgeons and interventional cardiologists, clinical trial specialists and statisticians, and representatives from the U.S. Food and Drug Administration considered all aspects of MV pathophysiology, prognosis, and therapies, culminating in a 2-part document describing consensus recommendations for clinical trial design (Part 1) and endpoint definitions (Part 2) to guide evaluation of transcatheter and surgical therapies for MR. The adoption of these recommendations will afford robustness and consistency in the comparative effectiveness evaluation of new devices and approaches to treat MR. These principles may be useful for regulatory assessment of new transcatheter MV devices, as well as for monitoring local and regional outcomes to guide quality improvement initiatives.

KEYWORDS:

heart failure; mitral regurgitation; mitral valve; valve intervention; valve surgery (or cardiac surgery)

PMID:
26184622
DOI:
10.1016/j.jacc.2015.05.046
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center